



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GSK3326595

Cat. No.:	HY-101563
CAS No.:	1616392-22-3
Molecular Formula:	C ₂₄ H ₃₂ N ₆ O ₃
Molecular Weight:	452.55
Target:	Histone Methyltransferase; SARS-CoV; MDM-2/p53; CDK; Apoptosis
Pathway:	Epigenetics; Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (138.11 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.2097 mL	11.0485 mL	22.0970 mL
	5 mM		0.4419 mL	2.2097 mL	4.4194 mL
	10 mM		0.2210 mL	1.1049 mL	2.2097 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: ≥ 2.5 mg/mL (5.52 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.52 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.08 mg/mL (4.60 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (4.60 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.60 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma

	[1][2][3][4][5]			
IC ₅₀ & Target	PRMT5	CDK4	CDK6	
In Vitro	GSK3326595 (10-100 nM, 24-72 h) inhibits SARS-CoV-2spike pseudovirus infection HEK-293 cells and A549 cells by attenuating ACE2-RBD interaction ^[1] . GSK3326595 (100 nM, 12 h) primes peritoneal macrophages to IFN-gamma-induced M1 polarization ^[3] . GSK3326595 (0.15-10 μM, 72 h) induces cell death in MCL cell ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[4]			
	Cell Line:	HEK-293T cells, A549 cells		
	Concentration:	10 nM, 25 nM, 50 nM, 100 nM		
	Incubation Time:	48 h		
	Result:	Strongly inhibited ACE2-RBD interaction at low concentration. Inhibited SARS-CoV-2 Omicron and other variants Spike1 binding with ACE2. Inhibits SARS-CoV-2 spike pseudovirus infection host cells.		
	Cell Cytotoxicity Assay ^[1]			
	Cell Line:	MCL cells		
	Concentration:	0.15 μM, 0.3 μM, 0.6 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM		
	Incubation Time:	72 h		
	Result:	Resulted in modest growth inhibition in MCL cells.		
	In Vivo	GSK3326595 (5 mg/kg, Intraperitoneal injection, three times a week for 9 weeks) increased hepatic triglyceride levels without affecting atherosclerosis in LDL receptor knockout mice ^[3] .GSK3326595 (25-50 mg/kg, Oral, once a day for 2 weeks) enhances the efficacy of anti-programed cell death protein 1 (PD-1) immune checkpoint therapy (ICT) in hepatocellular carcinoma (HCC) in myelocytomatosis transgene turned on (MYC-ON) mice ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
		Animal Model:	LDL receptor knockout mice ^[3]	
Dosage:		5 mg/kg		
Administration:		Intraperitoneal injection (i.p.)		
Result:		Did not alter atherosclerosis susceptibility. Increased hepatic triglyceride levels without changing the hyperlipidemia extent. Activated genes involved in fatty acid acquisition.		
Animal Model:		myelocytomatosis transgene turned on mice ^[5]		
Dosage:		25 mg/kg, 50 mg/kg		
Administration:		Oral		
Result:		Significantly suppressed tumor growth at 50 mg/kg. Showed better therapeutic efficacy at 25 mg/kg.		

CUSTOMER VALIDATION

- Nat Commun. 2021 Jun 8;12(1):3444.
- J Exp Clin Cancer Res. 2022 Oct 5;41(1):293.
- EMBO Mol Med. 2023 Jul 17;e17248.
- Cell Mol Life Sci. 2023 Jan 17;80(2):43.
- Oncogene. 2021 Apr;40(15):2711-2724.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Li Z, et al. GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation [J]. Journal of Medical Virology, 2023, 95(1): e28158.
- [2]. Fedoriw A, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss [J]. Cancer cell, 2019, 36(1): 100-114. e25.
- [3]. Zhang Y, et al. PRMT5 inhibition induces pro-inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice [J]. Journal of Cellular and Molecular Medicine, 2023, 27(8): 1056-1068.
- [4]. Che Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations [J]. Blood cancer journal, 2023, 13(1): 27.
- [5]. Luo Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 Axis defines the tumorigenesis and immune response in hepatocellular carcinoma [J]. Hepatology, 2021, 74(4): 1932-1951.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA